

23rd August, 2023

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our earlier letter dated 25-May-23 on the inspection conducted by USFDA for our Manufacturing facility at Dahej, Gujarat from 17-May-23 to 25-May-23.

In furtherance to the aforementioned intimation, this is to inform you that the USFDA has issued an Establishment Inspection Report (“EIR”) for the said manufacturing facility and the inspection has now been successfully closed by the USFDA.

Please take the information on your records.

Thanking you,

Yours faithfully,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN
MAHESHKU
MAR TRIVEDI
Digitally signed by
CHINTAN
MAHESHKUMAR
TRIVEDI
Date: 2023.08.23
23:54:56 +05'30'

CHINTAN M. TRIVEDI
COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com